Athira Pharma(US:ATHA)2025-11-06 21:09Financial Performance - Athira Pharma reported a net loss of $6.6 million, or $1.68 per share, for the quarter ended September 30, 2025, compared to a net loss of $28.7 million, or $7.46 per share, for the same period in 2024[9][17]. - Cash, cash equivalents, and investments totaled $25.2 million as of September 30, 2025, down from $51.3 million as of December 31, 2024[8]. - Total operating expenses for the quarter were $6.9 million, down from $29.6 million in the same quarter of 2024[8][17]. Research and Development - Research and Development (R&D) expenses were $2.8 million for the quarter ended September 30, 2025, significantly lower than $17.9 million for the same quarter in 2024[8][17]. - Athira conducted a Phase 1 clinical trial of ATH-1105, enrolling 80 healthy volunteers, which demonstrated a favorable safety profile and dose proportional pharmacokinetics[4][8]. - The company aims to advance ATH-1105 into clinical trials for ALS patients following promising Phase 1 results[2][4]. - Athira's drug development pipeline includes candidates targeting neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's[3][4]. Strategic Initiatives - The company is exploring strategic alternatives to maximize stockholder value and has engaged Cantor Fitzgerald & Co. as an advisor[8][9]. - A 10-for-1 reverse stock split was implemented on September 17, 2025, to enhance the stock's marketability[8]. General and Administrative Expenses - General and Administrative (G&A) expenses decreased to $4.1 million for the quarter ended September 30, 2025, compared to $7.6 million for the same quarter in 2024[8][17].